ATE383417T1 - Produktion lymphoider gewebsspezifischer zellen von hämatopoietischen vorläuferzellen in einem dreidimensionalen system - Google Patents

Produktion lymphoider gewebsspezifischer zellen von hämatopoietischen vorläuferzellen in einem dreidimensionalen system

Info

Publication number
ATE383417T1
ATE383417T1 AT99960304T AT99960304T ATE383417T1 AT E383417 T1 ATE383417 T1 AT E383417T1 AT 99960304 T AT99960304 T AT 99960304T AT 99960304 T AT99960304 T AT 99960304T AT E383417 T1 ATE383417 T1 AT E383417T1
Authority
AT
Austria
Prior art keywords
cells
lymphoid tissue
specific
production
dimensional system
Prior art date
Application number
AT99960304T
Other languages
English (en)
Inventor
Michael Rosenzweig
Mark Pykett
David T Scadden
Mark C Poznansky
Original Assignee
Cytomatrix Llc
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomatrix Llc, Gen Hospital Corp filed Critical Cytomatrix Llc
Application granted granted Critical
Publication of ATE383417T1 publication Critical patent/ATE383417T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99960304T 1998-11-12 1999-11-12 Produktion lymphoider gewebsspezifischer zellen von hämatopoietischen vorläuferzellen in einem dreidimensionalen system ATE383417T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10797298P 1998-11-12 1998-11-12

Publications (1)

Publication Number Publication Date
ATE383417T1 true ATE383417T1 (de) 2008-01-15

Family

ID=22319499

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99960304T ATE383417T1 (de) 1998-11-12 1999-11-12 Produktion lymphoider gewebsspezifischer zellen von hämatopoietischen vorläuferzellen in einem dreidimensionalen system

Country Status (9)

Country Link
US (1) US20080064101A1 (de)
EP (1) EP1135463B1 (de)
JP (1) JP2002529073A (de)
CN (1) CN1180079C (de)
AT (1) ATE383417T1 (de)
AU (1) AU1720400A (de)
CA (1) CA2351889A1 (de)
DE (1) DE69937966D1 (de)
WO (1) WO2000027999A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440734B1 (en) 1998-09-25 2002-08-27 Cytomatrix, Llc Methods and devices for the long-term culture of hematopoietic progenitor cells
US6548299B1 (en) * 1999-11-12 2003-04-15 Mark J. Pykett Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices
WO2001032841A2 (en) * 1999-10-29 2001-05-10 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Method of in vitro t cell differentiation of cd34+ progenitor cells
ES2522890T3 (es) 2000-12-06 2014-11-19 Anthrogenesis Corporation Método para recolectar células troncales placentarias
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
CA2437957C (en) 2001-02-14 2014-04-22 Robert J. Hariri Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
WO2003030965A2 (de) * 2001-09-27 2003-04-17 Martin Scholz Künstlicher lymphknoten
AUPS112802A0 (en) * 2002-03-15 2002-04-18 Monash University Methods of inducing differentiation of stem cells into a specific cell lineage
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CA2485332A1 (en) * 2002-05-24 2003-12-04 Cytomatrix, Llc Cytokine-free growth and maintenance of progenitor cells
CA2505534A1 (en) 2002-11-26 2004-06-10 Anthrogenesis Corporation Cytotherapeutics, cytotherapeutic units and methods for treatments using them
EP1576957A1 (de) * 2004-03-18 2005-09-21 Universiteit Twente Wiederherstellung zerstörten Gewebes mit Hilfe von pluripotenten Zellen
ATE447609T1 (de) * 2004-03-31 2009-11-15 Reliance Life Sciences Pvt Ltd GEWEBEARTIGE ORGANISATION VON ZELLEN UND MAKROSKOPISCHE GEWEBEARTIGE KONSTRUKTE, DIE DURCH ßMAKROMASS-KULTURß VON ZELLEN HERGESTELLT WERDEN, UND DIE METHODE DER ßMAKROMASS-KULTURß
CN100345963C (zh) * 2005-01-13 2007-10-31 中山大学 胚胎干细胞分化成t细胞的培养方法及分化培养基
DK1957633T3 (en) 2005-10-13 2014-03-17 Anthrogenesis Corp Immunomodulation USING PLACE SPEECH STEM CELLS
JP2009521930A (ja) 2005-12-29 2009-06-11 アントフロゲネシス コーポレーション 胎盤幹細胞及び第２供給源由来幹細胞の共存培養
KR20190104428A (ko) 2005-12-29 2019-09-09 안트로제네시스 코포레이션 태반 줄기 세포 집단
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
SI2120977T1 (sl) 2007-02-12 2014-01-31 Anthrogenesis Coroporation Zdravljenje vnetnih bolezni z uporabo placentarnih matičnih celic
JP5024823B2 (ja) * 2007-05-30 2012-09-12 独立行政法人産業技術総合研究所 細胞運動性評価セルチップ
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
WO2009045360A2 (en) 2007-09-28 2009-04-09 Celgene Cellular Therapeutics Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
WO2010071692A2 (en) 2008-06-18 2010-06-24 Innovative Biotherapies, Inc. Methods for enhanced propagation of cells
KR20240052847A (ko) 2008-08-20 2024-04-23 셀룰래리티 인코포레이티드 개선된 세포 조성물 및 그의 제조 방법
RU2562154C2 (ru) 2008-11-19 2015-09-10 Антродженезис Корпорейшн Амниотические адгезивные клетки
EP3284818B1 (de) 2010-01-26 2022-03-09 Celularity Inc. Behandlung von knochenbedingten karzinomen mit plazentastammzellen
TW201902496A (zh) 2010-04-07 2019-01-16 美商安瑟吉納西斯公司 利用胎盤幹細胞之血管新生
KR20190108599A (ko) 2010-07-13 2019-09-24 안트로제네시스 코포레이션 천연 킬러 세포의 생성 방법
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
CN113559126A (zh) 2011-06-01 2021-10-29 人类起源公司 利用胎盘干细胞治疗疼痛
CN102228719B (zh) * 2011-06-24 2013-12-18 中国人民解放军军事医学科学院基础医学研究所 一种组织工程化***模型及其构建方法
GB201116116D0 (en) * 2011-09-19 2011-11-02 Univ York Cell differentiation
CN115137753A (zh) 2013-02-05 2022-10-04 细胞结构公司 来自胎盘的自然杀伤细胞
US9775816B2 (en) 2013-11-07 2017-10-03 The General Hospital Corporation Eluting matrix and uses thereof
JP6474549B2 (ja) * 2014-03-03 2019-02-27 国立大学法人徳島大学 幹細胞の培養産物の評価指標及びその利用
US11419725B2 (en) * 2017-11-22 2022-08-23 Zimmer, Inc. Implants including a monolithic layer of biocompatible metallic material
CN113881631B (zh) * 2021-10-11 2022-08-02 北京翊博普惠生物科技发展有限公司 一种扁桃体来源的Tγδ细胞及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US544950A (en) * 1895-08-20 boucher
CA1282725C (en) * 1986-04-18 1991-04-09 Brian A. Naughton Process for replicating bone marrow in vitro and using the same
US5032508A (en) * 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
HU202578B (en) * 1986-04-18 1991-03-28 Marrow Tech Inc Process for repricating bone marrow celles in three-dimension celle-cultivating systhem, three-dimension vehicle for the systhem and process for testing citotoxicity of the systhem
US5266480A (en) * 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
WO1990015877A2 (en) * 1989-06-15 1990-12-27 The Regents Of The University Of Michigan Methods, compositions and devices for growing cells
US5763266A (en) * 1989-06-15 1998-06-09 The Regents Of The University Of Michigan Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells
US5635386A (en) * 1989-06-15 1997-06-03 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
US5635387A (en) * 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5262320A (en) * 1990-06-18 1993-11-16 Massachusetts Institute Of Technology Cell-culturing apparatus and method employing a macroporous support
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5282861A (en) * 1992-03-11 1994-02-01 Ultramet Open cell tantalum structures for cancellous bone implants and cell and tissue receptors
US5677139A (en) * 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
US6121042A (en) * 1995-04-27 2000-09-19 Advanced Tissue Sciences, Inc. Apparatus and method for simulating in vivo conditions while seeding and culturing three-dimensional tissue constructs
US6440734B1 (en) * 1998-09-25 2002-08-27 Cytomatrix, Llc Methods and devices for the long-term culture of hematopoietic progenitor cells
US6548299B1 (en) * 1999-11-12 2003-04-15 Mark J. Pykett Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices
EP1222248B1 (de) * 1999-09-24 2006-07-26 Cytomatrix, LLC Zellkulturspinnerflaschen
FR2832547A1 (fr) * 2001-11-21 2003-05-23 St Microelectronics Sa Procede de realisation d'une diode schottky sur substrat de carbure de silicium
CA2485332A1 (en) * 2002-05-24 2003-12-04 Cytomatrix, Llc Cytokine-free growth and maintenance of progenitor cells
EP1743025A4 (de) * 2004-03-29 2007-12-05 Cytomatrix Llc Herstellungsverfahren für regulator-t-zellen und deren verwendung

Also Published As

Publication number Publication date
DE69937966D1 (de) 2008-02-21
CN1180079C (zh) 2004-12-15
EP1135463A2 (de) 2001-09-26
EP1135463B1 (de) 2008-01-09
WO2000027999A9 (en) 2000-11-09
CN1326505A (zh) 2001-12-12
US20080064101A1 (en) 2008-03-13
CA2351889A1 (en) 2000-05-18
JP2002529073A (ja) 2002-09-10
WO2000027999A2 (en) 2000-05-18
WO2000027999A3 (en) 2000-08-03
AU1720400A (en) 2000-05-29

Similar Documents

Publication Publication Date Title
ATE383417T1 (de) Produktion lymphoider gewebsspezifischer zellen von hämatopoietischen vorläuferzellen in einem dreidimensionalen system
PT1428878E (pt) Processo para a produção e purificação de eritropoietina
SG152273A1 (en) Pdx1 expressing endoderm
AU641488B2 (en) Human hematopoietic stem cell
WO2005063971A3 (en) Definitive endoderm
WO2007051038A3 (en) Pdx1-expressing dorsal and ventral foregut endoderm
DE602005021379D1 (de) System und verfahren zur produktion von antikörpern in der pflanzenzellkultur
WO2001032830A3 (en) Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher basidiomycetes mushroom
ATE452664T1 (de) Verfahren und vorrichtung zum züchten von zellen
HK1027022A1 (en) Pellets derived from keratinocytes for use as wound healing substances
DE69939548D1 (de) Verfahren zur herstellung von faktor vii
WO2004090096A3 (en) Methods for neural differentiation of embryonic stem cells using protease passaging techniques
ATE378398T1 (de) Pluripotente embryonale keimzellinie aus vögeln
ATE324434T1 (de) Verfahren zur herstellung künstlicher pflanzenchromosomen
DK1495112T3 (da) Cellekulturmedium
WO2003010292A3 (en) Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
HK1048135A1 (zh) 具增強細胞活力功能的高產量的細胞變動素(cytokine)
EP0310056A3 (de) T-Zellen-Wachstumsfaktor aus Thymusdrüsen-Stroma und Verfahren zu seiner Herstellung
ATE321848T1 (de) Immobilisierungsträger mit einem porösen medium
NZ522337A (en) Production of TcR gamma delta T cells
ATE297981T1 (de) Herstellung von vakzinen unter der verwendung von hybrid-zellen
WO2003100010A3 (en) Cytokine-free growth and maintenance of progenitor cells
WO2003052064A3 (en) Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
WO1996007730A3 (de) Chemisches verfahren zur förderung der proliferation von tierischen zellen
AU4075093A (en) Cellular aggregate stabilized culture and process for the development of embryos from a proembryogenic strain for use in vine regeneration techniques

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties